Avita Medical Ltd. CEO William Dolphin, Ph.D. Interviewed by Stock News Now
(firmenpresse) - NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwire) -- 02/14/13 -- William Dolphin, Ph.D., the CEO of regenerative medicine company . (ASX: AVH) (OTCQX: AVMXY), was interviewed by SNNLive last week. Dr. Dolphin provides an update on Avita's flagship product, ReCell® SprayOn Skin®. Based on Avita's proprietary technology, ReCell is designed to provide a rapid, safe and effective point of care treatment for regrowing skin tissue that has been damaged due to trauma, disease, or senescence.
Dr. Dolphin emphasizes that ReCell® addresses a wide range of markets including "acute wounds, burns, chronic wounds, diabetic foot ulcers, venous leg ulcers, plastic reconstructive, acne scarring, and vitiligo." The interview showcases a comprehensive overview of Avita Medical, touching on company history, products overview, current and pending approvals, and market size potential. Dr. Dolphin also discusses Avita's strategy of building the foundation for growth via clinical studies, research and development, and reimbursement.
For more information, please visit Avita's website at .
Avita Medical () develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. An FDA trial on the safety and efficacy of ReCell is in process.
:
Avita Medical Ltd.
Stella Sung, Ph.D.
Business Development Officer
Phone:+1 838-352-9400
Email:
ProActive Capital Resources Group, LLC
Jeff Ramson
CEO
641 Lexington Avenue, 6th Floor
New York, NY. 10022
Phone:+1 646-863-6893
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.02.2013 - 08:00 Uhr
Sprache: Deutsch
News-ID 1197135
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 170 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Avita Medical Ltd. CEO William Dolphin, Ph.D. Interviewed by Stock News Now
"
steht unter der journalistisch-redaktionellen Verantwortung von
Avita Medical (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
